Monte Rosa Therapeutics/$GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
$GLUE
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
142
ISIN
US61225M1027
Website
GLUE Metrics
BasicAdvanced
$325M
68.27
$0.08
1.41
-
Price and volume
Market cap
$325M
Beta
1.41
52-week high
$10.11
52-week low
$3.50
Average daily volume
467K
Financial strength
Current ratio
5.611
Quick ratio
5.53
Long term debt to equity
13.81
Total debt to equity
15.214
Profitability
EBITDA (TTM)
6.143
Gross margin (TTM)
29.23%
Net profit margin (TTM)
3.86%
Operating margin (TTM)
-1.33%
Effective tax rate (TTM)
34.97%
Revenue per employee (TTM)
$1,120,000
Management effectiveness
Return on assets (TTM)
-0.40%
Return on equity (TTM)
2.88%
Valuation
Price to earnings (TTM)
68.271
Price to revenue (TTM)
2.634
Price to book
1.18
Price to tangible book (TTM)
1.18
Price to free cash flow (TTM)
13.783
Free cash flow yield (TTM)
7.26%
Free cash flow per share (TTM)
38.38%
Growth
Revenue change (TTM)
14,889.38%
Earnings per share change (TTM)
-103.10%
3-year earnings per share growth (CAGR)
-68.00%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
Bulls say / Bears say
Monte Rosa Therapeutics reported a first-quarter profit of $46.9 million, surpassing Wall Street expectations, with revenue of $84.9 million, significantly higher than the anticipated $25.3 million. (mrt.com)
The company entered into a strategic collaboration with Roche Holdings AG, receiving an upfront payment of $50 million and potential milestone payments exceeding $2 billion, enhancing its financial position and research capabilities. (benzinga.com)
Monte Rosa's lead asset, MRT-2359, is in an ongoing Phase 1/2 study for MYC-driven and high-grade neuroendocrine tumors, with interim data showing approximately 60% reduction in GSPT1 protein expression, indicating promising clinical activity. (benzinga.com)
Wells Fargo & Company downgraded Monte Rosa Therapeutics' stock rating from 'Overweight' to 'Equal Weight' and reduced the price target from $14.00 to $11.00, reflecting concerns about the company's future performance. (marketbeat.com)
Despite recent collaborations, Monte Rosa reported a loss from operations of $81.1 million in its annual 10-K report, indicating ongoing financial challenges. (tradingview.com)
The company's stock price remains volatile, with a 52-week range between $2.44 and $8.84, suggesting potential instability and investor uncertainty. (finance.yahoo.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Jun 2025.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
GLUE News
AllArticlesVideos
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
GlobeNewsWire·1 week ago
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
GlobeNewsWire·1 month ago
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $325M as of July 11, 2025.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 68.27 as of July 11, 2025.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.41. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.